T1	intervention 31 42	balugrastim
T4	control-participants 927 929	26
T5	intervention-participants 846 848	11
T6	intervention-participants 859 861	21
T7	intervention-participants 878 880	20
T8	outcome 1000 1027	incidence of adverse events
T9	outcome 1171 1182	neutropenia
T10	outcome 1184 1192	alopecia
T11	outcome 1198 1204	nausea
T12	outcome 1222 1240	severe neutropenia
T13	iv-bin-percent 1299 1301	40
T14	iv-bin-percent 1303 1305	67
T15	iv-bin-percent 1311 1315	50 %
T16	outcome 1320 1339	febrile neutropenia
T17	iv-bin-percent 1352 1356	20.0
T18	iv-bin-percent 1358 1361	9.5
T19	iv-bin-percent 1367 1373	10.0 %
T20	cv-bin-percent 1478 1482	48 %
T21	outcome 1495 1513	severe neutropenia
T22	cv-bin-percent 1518 1521	8 %
T23	outcome 1534 1553	febrile neutropenia
T24	outcome 1555 1591	Duration of severe neutropenia (DSN)
T25	iv-cont-mean 1621 1624	0.9
T26	iv-cont-mean 1626 1629	1.6
T27	iv-cont-mean 1631 1634	1.1
T28	cv-cont-mean 1640 1648	0.9 days
T2	control 902 915	pegfilgrastim
T3	outcome 1708 1711	DSN
